4 results match your criteria: "Centre d'Investigation Clinique (CIC) 1417[Affiliation]"
JAMA Netw Open
April 2024
INSERM, U1111, CNRS, UMR 5308, CIRI-GIMAP, Université Claude Bernard Lyon 1, Université Jean Monnet, Immunology and Immunomonitoring Laboratory, iBiothera, CIC 1408, Saint-Étienne, France.
Importance: There is still considerable controversy in the literature regarding the capacity of intramuscular messenger RNA (mRNA) vaccination to induce a mucosal immune response.
Objective: To compare serum and salivary IgG and IgA levels among mRNA-vaccinated individuals with or without previous SARS-CoV-2 infection.
Design, Setting, And Participants: In this cohort study, SARS-CoV-2-naive participants and those with previous infection were consecutively included in the CoviCompare P and CoviCompare M mRNA vaccination trials and followed up to day 180 after vaccination with either the BNT162b2 (Pfizer-BioNTech) vaccine or the mRNA-1273 (Moderna) vaccine at the beginning of the COVID-19 vaccination campaign (from February 19 to June 8, 2021) in France.
BMC Geriatr
August 2022
Université de Paris, Inserm, Centre d'Investigation Clinique (CIC) 1417, Assistance Publique - Hôpitaux de Paris, CIC Cochin-Pasteur, Hôpital Cochin, 27 Rue du Faubourg Saint-Jacques, Paris, France.
Background: In France, the increase in COVID-19 vaccine uptake among older adults slowed down between May and June 2021. Using the data from a national survey, we aimed to assess COVID-19 vaccine uptake among French residents aged 65 years and older, particularly at risk of severe form of the infection, and identify factors associated with non-vaccination.
Methods: A cross-sectional online survey collected the immunization status/intention to get the COVID-19 vaccine, reasons for vaccination/non-vaccination and factors potentially associated with vaccine uptake between May 10 and 23, 2021 among a large sample of French residents.
Rev Prat
May 2022
Assistance publique-Hôpitaux de Paris, hôpital Cochin, Inserm, centre d'investigation clinique (CIC) 1417, Paris, France - Université Paris Cité, Inserm, F-CRIN, I-REIVAC, COVIREIVAC, Paris, France.
ANTI-SARS-COV-2 VACCINATION, THE GRAIL? The Covid-19 pandemic, which caused an unprecedented health crisis, was partially controlled by the rapid development of effective vaccines against SARS-CoV-2. To date, 5 vaccines are approved in Europe, 10 are recognized by the World Health Organization and more than 150 vaccine candidates are in clinical development. This emerging pandemic disease context has shown the value of research and real-life data.
View Article and Find Full Text PDFNat Med
February 2022
VITROME (Aix Marseille Université, IRD, AP-HM, SSA), Marseille, France.